Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RO4905417 (HuMAb P-Selectin) in Non-STEMI Patients Undergoing PCI
2011-001365-40Phase 2Completed
- Sponsor
- Roche
- Start
- Dec 2011
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of inclacumab in Non-ST-segment elevation myocardial infarction (NSTEMI) (3 arms), sponsored by Roche. Primary endpoint: Change in troponin I levels early after PCI. Started Dec 2011; status: completed.
02
Drugs
inclacumab
03
Conditions
Non-ST-segment elevation myocardial infarction (NSTEMI)
Beyond the preview
Go deeper on 2011-001365-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-001365-40.